https://www.yiliao.com/index.php?action=history&feed=atom&title=Farletuzumab
Farletuzumab - 版本历史
2026-04-18T12:38:33Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Farletuzumab&diff=314602&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T02:43:41Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[法列图珠单抗]]</strong>（<strong>[[Farletuzumab]]</strong>，研发代码：<strong>[[MORAb-003]]</strong>）是一种重组人源化单克隆抗体，特异性靶向<strong>[[叶酸受体α]]</strong>（[[FRα]]，由[[FOLR1]]基因编码）。作为一种[[IgG1]]型抗体，[[法列图珠单抗]]通过与[[FRα]]高亲和力结合，旨在通过[[抗体依赖性细胞介导的细胞毒作用]]（[[ADCC]]）和[[补体依赖的细胞毒作用]]（[[CDC]]）清除高表达该受体的肿瘤细胞。临床上，它曾被广泛探索用于治疗<strong>[[卵巢癌]]</strong>及某些类型的[[非小细胞肺癌]]。尽管早期单药试验显示出良好的耐受性，但目前的研究重点已转向其[[抗体偶联药物]]（[[ADC]]）形式的演进，以克服传统单抗在晚期实体瘤中应答率有限的挑战。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[法列图珠单抗]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[Farletuzumab]] / [[MORAb-003]] · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[FRα]]靶向抗体结构模型</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[FOLR1]] (FRα)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2348([[FOLR1]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P15328</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[人源化单克隆抗体]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[分子量]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约145kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方式</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[静脉滴注]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">开发厂商</th><br />
<td style="padding: 12px; color: #0f172a;">[[Eisai]] (卫材)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多维免疫打击与信号阻断</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[法列图珠单抗]]的作用机制复杂，主要通过免疫应答和胞内信号干扰实现抑瘤效果：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>免疫效应募集：</strong>作为[[IgG1]]抗体，其[[Fc段]]能结合[[自然杀伤细胞]]（[[NK细胞]]）表面的[[CD16]]受体，诱导[[ADCC]]；同时激活补体系统引发[[CDC]]，通过形成[[膜攻击复合物]]（MAC）直接裂解肿瘤细胞。</li><br />
<li style="margin-bottom: 12px;"><strong>信号通路抑制：</strong>[[法列图珠单抗]]与[[FRα]]结合后，可干扰受体与下游[[LYN激酶]]的互作，从而抑制促进细胞存活和增殖的信号传导。</li><br />
<li style="margin-bottom: 12px;"><strong>自噬诱导与凋亡：</strong>部分研究表明，该药可能通过阻断[[叶酸]]摄取的部分非经典途径（如非转运依赖型信号），诱导肿瘤细胞进入[[自噬]]或[[凋亡]]程序。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：从单抗到ADC的演进</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床试验代号</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究设计/受试人群</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">关键结论与趋势</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[MORAb-003-003]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">III期：联合铂类化疗治疗铂敏感复发性卵巢癌。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">全人群未达到 [[PFS]] 主要终点，但在低 [[CA-125]] 水平亚组中显示获益趋势。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[MORAb-202]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[Farletuzumab Ecteribulin]]：法列图珠单抗偶联[[艾立布林]]。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">新一代 [[ADC]] 形式，显著提升了对低/中表达 [[FRα]] 肿瘤的杀伤力。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：基于受体表达的精准分层</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[法列图珠单抗]]及其衍生药物的应用高度依赖于对病灶分子特性的深度识别：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[FRα]]表达量筛选：</strong>临床推荐使用[[免疫组化]]（[[IHC]]）评估肿瘤组织的受体表达强度（[[PS]]得分）。高表达人群（如得分≥75%）是该靶向方案的最优受试群体。</li><br />
<li style="margin-bottom: 12px;"><strong>[[生物标志物]]联合监测：</strong>[[CA-125]]水平与该药的应答强度存在负相关性，反映了肿瘤负荷及循环抗体捕获对药效的影响。</li><br />
<li style="margin-bottom: 12px;"><strong>克服免疫逃逸：</strong>由于单抗可能引发[[调节性T细胞]]（Tregs）募集，目前的策略倾向于将其与[[免疫检查点抑制剂]]或局部化疗序贯联用。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[FOLR1]]：</strong>编码[[叶酸受体α]]的基因，在正常上皮组织表达极低，在卵巢癌中广泛高表达。</li><br />
<li style="margin-bottom: 8px;"><strong>[[ADCC]]：</strong>抗体介导的靶细胞裂解，是[[法列图珠单抗]]发挥药效的核心免疫逻辑。</li><br />
<li style="margin-bottom: 8px;"><strong>[[艾立布林]] (Ecteribulin)：</strong>常作为法列图珠单抗 [[ADC]] 演进版本的强效载荷。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Mirvetuximab Soravtansine]]：</strong>同一靶点的竞争性 [[ADC]] 药物，已获得临床应用批准。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Vergote I, et al. (2016).</strong> <em>Farletuzumab in combination with platinum-based chemotherapy in patients with platinum-sensitive ovarian cancer: a randomized, double-blind, placebo-controlled, phase III study.</em> <strong>[[Journal of Clinical Oncology]]</strong>. 34(11):1187-1194.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该项III期研究虽然未达整体生存终点，但为后续FRα靶点的亚群筛选及ADC药物开发提供了关键数据基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Konner JA, et al. (2010).</strong> <em>Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.</em> <strong>[[Clinical Cancer Research]]</strong>. 16(21):5288-5295.<br><br />
<span style="color: #475569;">[核心价值]：首次在临床中验证了法列图珠单抗在人体内的安全性和靶向FRα的选择性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[法列图珠单抗]] 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FOLR1]]•[[LYN]]•[[Folic Acid]]•[[CA-125]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">演进版本</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Farletuzumab Ecteribulin]] ([[MORAb-202]])</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Eisai]] (卫材)•[[Bristol-Myers Squibb]] (BMS)•[[FDA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ADC载荷优化]]•[[FRα低表达人群获益]]•[[法列图珠单抗与PARP抑制剂协同]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164